Genomic Urine Testing Market Report 2026

The genomic urine testing market size has grown rapidly in recent years. It will grow from $1.01 billion in 2025 to $1.13 billion in 2026 at a compound annual growth rate (CAGR) of 12.5%. The growth in the historic period can be attributed to advances in molecular diagnostics, need for non-invasive testing, early biomarker research, laboratory adoption of genomic assays, oncology diagnostics growth.

The genomic urine testing market size is expected to see rapid growth in the next few years. It will grow to $1.8 billion in 2030 at a compound annual growth rate (CAGR) of 12.2%. The growth in the forecast period can be attributed to integration with routine health screening, expansion into infectious disease detection, technological improvements in sensitivity, personalized monitoring demand, clinical validation studies. Major trends in the forecast period include increasing adoption of non-invasive diagnostic testing, rising use of genomic biomarkers in disease detection, growing demand for early cancer screening tools, expansion of personalized diagnostic approaches, increased research in urinary genomic profiling.

The growing burden of chronic kidney disease (CKD) is expected to drive the expansion of the genomic urine testing market in the coming years. Chronic kidney disease is a condition in which the kidneys become damaged and lose their ability to effectively filter blood, resulting in the accumulation of waste products and excess fluids in the body. The prevalence of CKD is increasing largely due to the rising incidence of diabetes, as prolonged high blood sugar levels damage renal blood vessels and impair kidney filtration function. Genomic urine testing supports CKD management by enabling early identification of genetic markers, which allows for timely clinical interventions and the development of personalized treatment strategies. This approach improves patient outcomes by facilitating more precise disease monitoring and helping slow disease progression. For example, in November 2025, The American Journal of Managed Care, a US-based peer-reviewed medical journal, reported that approximately 788 million adults aged 20 years and older were living with chronic kidney disease in 2023. As a result, the increasing burden of CKD is fueling growth in the genomic urine testing market.

Key companies operating in the genomic urine testing market are concentrating on the development of innovative technologies, such as next-generation sequencing (NGS), to improve the accuracy, sensitivity, and early detection capabilities of non-invasive diagnostic tests for a range of diseases. Next-generation sequencing is an advanced DNA sequencing technology that enables rapid, high-throughput, and precise analysis of genetic material by simultaneously sequencing millions of DNA fragments. For instance, in May 2023, Convergent Genomics Inc., a US-based biotechnology company, introduced the genomic urine test UroAmp. This test employs next-generation DNA sequencing to analyze mutations across 60 genes linked to bladder cancer, allowing for early detection up to 12 years before the onset of clinical symptoms. UroAmp delivers detailed genetic information to support diagnosis, treatment decision-making, and recurrence monitoring, offering greater accuracy compared to conventional methods such as cytology and cystoscopy.

In September 2024, A. Menarini Diagnostics, an Italy-based in vitro diagnostics company, entered into a partnership with Nucleix Ltd. The collaboration focuses on the commercialization and distribution of Bladder EpiCheck, a non-invasive, urine-based genomic test designed for the early detection and monitoring of bladder and upper tract urothelial cancers across Europe. This partnership aims to improve access to advanced cancer diagnostic solutions while aligning with established European clinical guidelines. Nucleix Ltd. is an Israel-based molecular diagnostics company specializing in epigenetic and genomic testing technologies.

Major companies operating in the genomic urine testing market are Eurofins Scientific SE, Thermo Fisher Scientific, Abbott Laboratories, Laboratory Corporation of America Holdings, Hologic Inc., Illumina Inc., Myriad Genetics Inc., ARUP Laboratories, MedGenome Labs Ltd, GENETWORx LLC, MDxHealth SA, Nucleix Ltd., ​Pacific Edge Ltd, Convergent Genomics Inc., LynxDx Inc., miR Scientific, RYND Biotech, UGenDx Ltd.

North America was the largest region in the genomic urine testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic urine testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the genomic urine testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the genomic urine testing market by increasing costs of imported reagents, testing kits, and molecular diagnostic instruments. Diagnostic laboratories and hospitals are most affected due to dependence on imported consumables. These tariffs raise testing costs by increasing per-sample reagent expenses and instrument maintenance costs, potentially limiting routine adoption of genomic urine assays. However, they support local assay manufacturing, encouraging domestic production of reagents and test kits and improving long-term supply stability.

The genomic urine testing market research report is one of a series of new reports that provides genomic urine testing market statistics, including genomic urine testing industry global market size, regional shares, competitors with a genomic urine testing market share, detailed genomic urine testing market segments, market trends and opportunities, and any further data you may need to thrive in the genomic urine testing industry. This genomic urine testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Genomic urine testing is a non-invasive diagnostic approach that examines genetic material found in urine to identify specific biomarkers associated with diseases such as cancer, infections, or genetic disorders. This method integrates genomics with advanced molecular techniques to detect mutations, gene expression profiles, or microbial deoxyribonucleic acid (DNA). Its primary objective is to support early diagnosis, disease monitoring, and personalized treatment planning across various medical conditions.

The key testing types in genomic urine testing include deoxyribonucleic acid testing, ribonucleic acid testing, microbial testing, and epigenetic testing. Deoxyribonucleic acid (DNA) testing is a scientific technique used to analyze an individual’s genetic material to establish relationships, verify identity, or identify inherited conditions. These tests are distributed through multiple channels, including hospital pharmacies, mail-order pharmacies, and specialty pharmacies. Genomic urine testing is applied in areas such as cancer diagnosis, infectious disease detection, genetic disorder screening, and general health monitoring, and is used by a broad range of end users including hospitals and clinics, diagnostic laboratories, research and academic institutions, and other healthcare providers.

The genomic urine testing market includes of revenues earned by entities by providing services such as early disease detection, genetic mutation analysis, cancer screening, infection diagnostics, personalized treatment planning, and monitoring of disease progression through non-invasive urine-based genomic profiling. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.